Equities Analysts Offer Predictions for Endologix, Inc.’s Q1 2021 Earnings (NASDAQ:ELGX)

Share on StockTwits

Endologix, Inc. (NASDAQ:ELGX) – Analysts at Piper Jaffray Companies issued their Q1 2021 earnings estimates for Endologix in a research report issued on Wednesday, November 6th. Piper Jaffray Companies analyst M. O’brien expects that the medical instruments supplier will post earnings per share of ($0.23) for the quarter. Piper Jaffray Companies also issued estimates for Endologix’s Q2 2021 earnings at ($0.18) EPS, Q3 2021 earnings at ($0.20) EPS and FY2022 earnings at ($0.76) EPS.

Endologix (NASDAQ:ELGX) last released its quarterly earnings data on Wednesday, November 6th. The medical instruments supplier reported ($0.55) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.63) by $0.08. The business had revenue of $35.78 million during the quarter, compared to analysts’ expectations of $35.26 million. Endologix had a negative net margin of 60.32% and a negative return on equity of 120.57%.

Other equities research analysts have also issued research reports about the stock. Royal Bank of Canada set a $7.00 price target on shares of Endologix and gave the company a “hold” rating in a report on Friday, August 9th. ValuEngine lowered shares of Endologix from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Finally, Zacks Investment Research lowered shares of Endologix from a “hold” rating to a “sell” rating in a report on Friday. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $7.17.

Shares of Endologix stock traded up $0.12 during trading on Friday, hitting $3.00. 196,400 shares of the stock were exchanged, compared to its average volume of 230,126. The stock has a market cap of $48.61 million, a price-to-earnings ratio of -0.42 and a beta of 0.26. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.53 and a quick ratio of 1.80. The firm’s 50-day moving average price is $3.44 and its 200 day moving average price is $5.71. Endologix has a 12-month low of $2.28 and a 12-month high of $12.95.

A number of institutional investors have recently made changes to their positions in the business. First Light Asset Management LLC acquired a new position in Endologix in the second quarter valued at approximately $17,828,000. Morgan Stanley grew its position in shares of Endologix by 1,395.2% during the second quarter. Morgan Stanley now owns 722,419 shares of the medical instruments supplier’s stock worth $5,230,000 after purchasing an additional 674,103 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Endologix by 32.6% during the second quarter. Vanguard Group Inc. now owns 692,351 shares of the medical instruments supplier’s stock worth $5,012,000 after purchasing an additional 170,316 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Endologix by 868.3% during the second quarter. Renaissance Technologies LLC now owns 613,906 shares of the medical instruments supplier’s stock worth $4,445,000 after purchasing an additional 550,506 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. grew its position in shares of Endologix by 6.9% during the second quarter. D. E. Shaw & Co. Inc. now owns 177,931 shares of the medical instruments supplier’s stock worth $1,288,000 after purchasing an additional 11,497 shares in the last quarter. 77.88% of the stock is currently owned by hedge funds and other institutional investors.

About Endologix

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.

Further Reading: Stocks Increasing Dividends

Earnings History and Estimates for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.